Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

February 28, 2006

Conditions
Drug/Agent Toxicity by Tissue/OrganPancreatic Cancer
Interventions
DRUG

fluorouracil

High dose 5-FU

DRUG

gemcitabine hydrochloride

Normal dose to treat pancreatic cancer

DRUG

triacetyluridine

6 grams (12 tablets)

Trial Locations (29)

10021

New York Weill Cornell Cancer Center at Cornell University, New York

11365

Queens Medical Associates, PC, Fresh Meadows

19140

Fox Chase - Temple Cancer Center, Philadelphia

20878

Wellstat Therapeutics, Gaithersburg

29615

Cancer Centers of the Carolinas - Eastside, Greenville

31419

St. Joseph's Hospital, Savannah

32207

Florida Oncology Associates - South Side, Jacksonville

33021

Memorial Cancer Institute at Memorial Regional Hospital, Hollywood

33065

Northwest Oncology and Hematology Associates, Coral Springs

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

33908

Florida Cancer Specialists - World Plaza, Fort Myers

34655

Florida Cancer Institute - New Port Richey, New Port Richey

35294

Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham

44304

Summit Oncology Associates, Akron

47150

Cancer Care Center, New Albany

55416

CCOP - Metro-Minnesota, Saint Louis Park

63141

David C. Pratt Cancer Center at St. John's Mercy, St Louis

65109

Capitol Comprehensive Cancer Care Clinic, Jefferson City

78412

Corpus Christi Cancer Center, Corpus Christi

91505

Providence Saint Joseph Medical Center - Burbank, Burbank

92037

Scripps Cancer Center at Scripps Clinic, La Jolla

35209-6804

Brookwood Medical Center, Birmingham

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

21204-6881

Cancer Center at Greater Baltimore Medical Center, Baltimore

87131-5636

University of New Mexico Cancer Research and Treatment Center, Albuquerque

17033-0850

Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey

K1H 1C4

Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus, Ottawa

P7B 6V4

Regional Cancer Care at Thunder Bay Regional Health Sciences Centre, Thunder Bay

H2W 1S6

McGill Cancer Centre at McGill University, Montreal

All Listed Sponsors
lead

Wellstat Therapeutics

INDUSTRY

NCT00024427 - Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter